23:38 , Oct 18, 2017 |  BC Innovations  |  Translation in Brief

Neutrophil bias

Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory phenotype in neutrophils that can treat stroke in mice. But safety issues around the recombinant cytokine have the team...
01:21 , Jan 27, 2017 |  BC Innovations  |  Targets & Mechanisms

Death metal

The findings in two high profile papers on ferroptosis could be the nudge the fledgling field needs to gain the attention of drug developers. The process is the latest cell death pathway to offer up...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Ferriprox deferiprone regulatory update

EMA’s CHMP recommended approving an expanded label for iron chelating agent Ferriprox deferiprone from Apotex to treat iron overload in patients with thalassemia. The agency recommends approval of Ferriprox, which is indicated for use when...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Polymer matrix transdermal drug delivery system

Drug delivery TECHNOLOGY: Polymers Mouse studies suggest drug-encapsulating polymer micelles could be useful for topical treatment of diabetic ulcers. In ex vivo human skin samples and normal mice, topically administered polymeric micelles encapsulating the generic...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

Exjade deferasirox regulatory update

EMA's CHMP recommended against expanding the label of Exjade deferasirox from Novartis to include first-line treatment of chronic iron overload in patients ages >=6 years with beta thalassemia major who receive infrequent blood transfusions. The...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Clinical News

Exjade deferasirox regulatory update

On Dec. 21, 2012, Novartis said that the European Commission approved a label expansion for Exjade deferasirox to treat chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients ages...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Exjade deferasirox regulatory update

EMA's CHMP issued a positive opinion recommending expanding the label of Exjade deferasirox to include treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients >=10 years of...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

Ferriprox deferiprone regulatory update

FDA granted accelerated approved to an NDA from Apotex for Ferriprox to treat transfusional iron overload in patients with thalassemia when current chelation therapy is inadequate. The label includes a boxed warning about the risk...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Clinical News

Ferriprox deferiprone regulatory update

FDA's Oncologic Drugs Advisory Committee voted 10-2 that Ferriprox deferiprone has a favorable benefit-risk profile to treat transfusional iron overload when current chelation therapy is inadequate. The committee recommended accelerated approval of the oral iron...
00:23 , Sep 15, 2011 |  BC Extra  |  Company News

FDA panel backs Apotex's Ferriprox

FDA's Oncologic Drugs Advisory Committee voted 10-2 on Wednesday that Ferriprox deferiprone from Apotex Inc. (Toronto, Ontario) has a favorable benefit-risk profile to treat transfusional iron overload when current chelation therapy is inadequate. The committee...